# Memorial Sloan Kettering Cancer Center: Phase 2 study completed, 24 enrolled (Non-sclerotic Cutaneous Chronic Graft-versus-host Disease)

**Score:** 70/100

| Field | Value |
|---|---|
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Sponsor type | Academic and hospital |
| Study | Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease |
| NCT ID | NCT03954236 |
| Phase | Phase 2 |
| Status | completed |
| Conditions | Non-sclerotic Cutaneous Chronic Graft-versus-host Disease |
| Intervention types | drug, other |
| Target enrollment | 24 |
| Site countries | United States |
| Posted | 2019-05-17 |
| Planned start | 2019-05-14 |
| Event | Completed |
| Event date | 2026-10-12 |
| Last update posted | 2026-10-29 |

## Why this score
- Posted in the last two weeks.
- Completed: closeout, analysis and the next study ahead.
- Phase 2: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT03954236). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.